Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

      BioLineRx Ltd. Logo (PRNewsfoto/BioLineRx Ltd.)

      News provided by

      BioLineRx Ltd.

      Nov 25, 2024, 07:00 ET

      Share this article

      Share this article


      - Executed license agreement with Ayrmid Ltd. for APHEXDA® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales -

      - Received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC -

      - Entered into agreement to reduce and restructure long-term debt by ~$16.5 million -

      - Annual operational expenses expected to decline by over 70% following out-license of APHEXDA® (motixafortide) commercial program to Ayrmid -

      - Company to continue to support motixafortide PDAC program while evaluating additional assets for development in rare diseases and oncology -

      - Management to host conference call today, November 25, at 8:30 am EDT -

      TEL AVIV, Israel, Nov. 25, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2024, and provided updates on strategic actions designed to drive shareholder value.

      "The license agreement for APHEXDA that we announced last week was made possible by the tremendous work of our commercial team, who through their hard work proved the significant value that APHEXDA can bring to transplant centers and patients," said Philip Serlin, Chief Executive Officer of BioLineRx. "Our launch progress attracted Ayrmid, who will now, through Gamida Cell, continue to build on the strong commercial foundation that has been laid. We would like to thank our employees for their outstanding contributions to APHEXDA growth and expect this innovative product to reach even more patients with the additional resources from Ayrmid.

      "Looking forward, our streamlined and nimble company has a new financial foundation supported by sales royalties and potential milestone payments, which will allow our experienced team to develop important new therapies in rare disease and oncology that address areas with high unmet need. We will also focus on advancing our motixafortide PDAC program through existing collaborations that require de-minimis investment. Through this strategy, we anticipate delivering near- and long-term value for our shareholders," Mr. Serlin concluded. 

      Corporate Updates

      • Executed license agreement with Ayrmid Ltd. to develop and commercialize APHEXDA® (motixafortide) in all indications except solid tumors, and across all territories except Asia
        • License agreement included a $10 million upfront payment, up to $87 million in potential commercial milestones, and royalties on net sales ranging from 18% to 23%
        • BioLineRx will supply motixafortide on a cost-plus basis, for both commercial and development supply
        • Certain members of the BioLineRx U.S.-based commercial organization will be transitioned to Ayrmid Pharma Ltd.
      • Received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC, to support BioLineRx's pipeline expansion
      • Operating expense run-rate expected to decrease by more than 70% beginning January 1, 2025 through APHEXDA commercial program transfer and additional headcount reductions
      • Company intends to evaluate additional asset opportunities in 2025, with a focus on early-stage clinical programs in oncology or rare diseases that address major areas of unmet need

      Financial Updates

      • Executed repayment and restructuring agreement with BlackRock EMEA Venture and Growth Lending to repay $16.5 million of approximately $29 million in total debt due; remaining balance will be paid over the next three years at the existing fixed annual interest rate of 9.5 percent
      • As of September 30, 2024, the Company had cash, cash equivalents, and short-term bank deposits of $29.2 million
      • Following the out-license to Ayrmid, the equity investment from Highbridge and the debt repayment to Blackrock, the Company's cash, cash equivalents and short-term bank deposits are expected to be approximately $20 million, which management believes will be sufficient to fund operations into 2026, as currently planned

      APHEXDA Launch Updates

      • Aphexda achieved 10 percent market share milestone of total CXCR4 inhibitor usage in the U.S., which compares APHEXDA to branded MOZOBIL and generic plerixafor in all indications
      • Institutions ordering APHEXDA increased by 40 percent in the third quarter

      Clinical Portfolio Updates
      Motixafortide

      Pancreatic Ductal Adenocarcinoma (mPDAC)

      • Continued enrollment in the CheMo4METPANC Phase 2b clinical trial collaboration with Columbia University. In addition to Columbia, patient enrollment has begun at Brown University, and three additional sites are anticipated to begin enrollment over the next two quarters. Full enrollment in the randomized trial targeting 108 patients is anticipated in 2027, with a prespecified interim futility analysis planned when 40% of PFS events are observed   

      Multiple Myeloma

      • Collaboration partner Gloria Biosciences' stem cell mobilization bridging study IND was filed and approved by the Center for Drug Evaluation of the National Medical Products Administration in China. Anticipate initiation of pivotal clinical trial in 1H 2025
      • Gloria Biosciences has received regulatory approval to commercialize APHEXDA in the Boao Region of China and Macao, areas in Asia that do not require a bridging study 

      Sickle Cell Disease (SCD) & Gene Therapy

      • Announced oral presentation at ASH 2024 on initial results from a Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD). Sponsored by investigators at Washington University in St. Louis, the findings from this proof-of-concept study suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle. The presentation will occur at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition taking place December 7-10, 2024, in San Diego, California

      Third Quarter 2024 Financial Results

      • Total revenue for the three months ended September 30, 2024 was $4.9 million. The Company did not record any revenue during the third quarter of 2023. Revenue for the quarter reflects a portion of the upfront payment from the Gloria Biosciences license, which amounted to $3.2 million, as well as $1.7 million of net revenue from product sales of APHEXDA in the U.S.
      • Cost of revenue for the three months ended September 30, 2024 was $0.8 million. The Company did not record any cost of revenue during the third quarter of 2023. Cost of revenue for the quarter primarily reflects the amortization of intangible assets, royalties on net product sales of APHEXDA in the U.S., and cost of goods sold on product sales
      • Research and development expenses for the three months ended September 30, 2024 were $2.6 million, compared to $2.7 million for the same period in 2023. The decrease resulted primarily from lower expenses related to the termination of the development of AGI-134 and a decrease in payroll and share-based compensation
      • Sales and marketing expenses for the three months ended September 30, 2024 were $5.5 million, compared to $8.1 million for the same period in 2023. The decrease resulted primarily from lower expenses of commercialization activities related to motixafortide. The higher expenses in the corresponding period of 2023 reflect the ramp-up of pre-commercialization activities related to motixafortide
      • General and administrative expenses for the three months ended September 30, 2024 were $1.4 million, compared to $1.5 million for the same period in 2023. The decrease resulted primarily from small decreases in a number of G&A expenses
      • Net loss for the three months ended September 30, 2024 was $5.8 million, compared to net loss of $16.0 million for the same period in 2023. The net loss for the 2024 period included $0.8 million in non-operating income, compared to non-operating expenses of $3.1 million for the same period in 2023, both primarily related to non-cash revaluation of warrants
      • As of September 30, 2024, the Company had cash, cash equivalents, and short-term bank deposits of $29.2 million.

      Third Quarter Results Conference Call and Webcast
      BioLineRx will report its third quarter 2024 results on November 25, 2024. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until November 27, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

      About BioLineRx
      BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding Asia) and Gloria Biosciences (in Asia). BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside.

      Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn. 

      Cautionary Note Regarding Forward-Looking Statements (BioLineRx)
      Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the potential success of the license agreement with Ayrmid, expectations with regard to clinical trials of motixafortide, statements relating to the equity investment offering, including as to the consummation of the offering described above, the expected gross proceeds therefrom and the timing of the closings of the offering and the license agreement. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials, and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether BioLineRx's collaboration partners will be able to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates, including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, operationalize and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the  commercial launch of APHEXDA; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; statements as to the impact of the political and security situation in Israel on BioLineRx's business; and the impact of the COVID-19 pandemic, the Russian invasion of Ukraine, the declared war by Israel against Hamas and the military campaigns against Hamas and other terrorist organizations, which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 26, 2024. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

      Contacts:

      United States
      John Lacey
      BioLineRx
      [email protected]

      Israel
      Moran Meir
      LifeSci Advisors, LLC
      [email protected]

      BioLineRx Ltd.

      CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

       (UNAUDITED)






      December 31,


      September 30,


      2023


      2024


      in USD thousands

      Assets




      CURRENT ASSETS




      Cash and cash equivalents

      4,255


      8,836

      Short-term bank deposits

      38,739


      20,337

      Trade receivables

      358


      3,611

      Prepaid expenses

      1,048


      1,171

      Other receivables

      830


      350

      Inventory

      1,953


      3,544

                Total current assets

      47,183


      37,849





      NON-CURRENT ASSETS




      Property and equipment, net

      473


      249

      Right-of-use assets, net

      1,415


      1,398

      Intangible assets, net

      14,854


      13,246

                Total non-current assets

      16,742


      14,893

                Total assets

      63,925


      52,742





      Liabilities and equity




      CURRENT LIABILITIES




      Current maturities of long-term loan

      3,145


      9,822

      Contract liabilities

      12,957


      2,255

      Accounts payable and accruals:




           Trade

      10,869


      4,633

           Other

      3,353


      3,370

      Current maturities of lease liabilities

      528


      517

      Warrants

      11,932


      4,365

                Total current liabilities

      42,784


      24,962

      NON-CURRENT LIABILITIES




      Long-term loan, net of current maturities

      6,628


      17,982

      Lease liabilities

      1,290


      1,293

                Total non-current liabilities

      7,918


      19,275

      CONTINGENT LIABILITIES




           Total liabilities

      50,702


      44,237





      EQUITY




      Ordinary shares

      31,355


      34,430

      Share premium

      355,482


      353,005

      Warrants

      1,408


      1,408

      Capital reserve

      17,000


      17,718

      Other comprehensive loss

      (1,416)


      (1,416)

      Accumulated deficit

      (390,606)


      (396,640)

                Total equity

      13,223


      8,505

                Total liabilities and equity

      63,925


      52,742

      BioLineRx Ltd.

      CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

      (UNAUDITED)



      Three months ended September 30,


       Nine months ended September 30,


      2023


      2024


      2023


      2024


      in USD thousands


      in USD thousands

      REVENUES

      -


      4,943


      -


      17,191

      COST OF REVENUES

      -


      (822)


      -


      (3,174)

      GROSS PROFIT

      -


      4,121


      -


      14,017

      RESEARCH AND DEVELOPMENT EXPENSES

      (2,727)


      (2,565)


      (9,417)


      (7,284)

      SALES AND MARKETING EXPENSES

      (8,131)


      (5,553)


      (17,609)


      (18,310)

      GENERAL AND ADMINISTRATIVE EXPENSES

      (1,499)


      (1,390)


      (4,102)


      (4,405)

      OPERATING LOSS

      (12,357)


      (5,387)


      (31,128)


      (15,982)

      NON-OPERATING INCOME (EXPENSES), NET

      (3,141)


      756


      (13,790)


      13,053

      FINANCIAL INCOME

      312


      434


      1,289


      1,534

      FINANCIAL EXPENSES

      (837)


      (1,625)


      (3,101)


      (4,639)

      NET LOSS AND COMPREHENSIVE LOSS

      (16,023)


      (5,822)


      (46,730)


      (6,034)










      in USD


      in USD

      LOSS PER ORDINARY SHARE - BASIC AND DILUTED

      (0.02)


      (0.00)


      (0.05)


      (0.01)









      WEIGHTED AVERAGE NUMBER OF SHARES USED IN
           CALCULATION OF LOSS PER ORDINARY SHARE

      929,058,619


      1,199,485,845


      925,014,511


      1,161,448,634









      BioLineRx Ltd.

      CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

      (UNAUDITED)



      Ordinary


      Share




      Capital


      Other

      comprehensive


      Accumulated




      shares


      premium


      Warrants


      reserve


      loss


      deficit


      Total


      in USD thousands

      BALANCE AT JANUARY 1, 2023

      27,100


      338,976


      1,408


      14,765


      (1,416)


      (329,992)


      50,841

      CHANGES FOR NINE MONTHS ENDED
           SEPTEMBER 30, 2023:














      Issuance of share capital, net

      361


      1,535


      -


      -


      -


      -


      1,896

      Warrants exercised

      865


      4,855


      -


      -


      -


      -


      5,720

      Employee stock options exercised

      6


      18


      -


      (9)


      -


      -


      15

      Employee stock options expired

      -


      78


      -


      (78)


      -


      -


      -

      Share-based compensation  

      -


      -


      -


      1,392


      -


      -


      1,392

      Comprehensive loss for the period

      -


      -


      -


      -


      -


      (46,730)


      (46,730)

      BALANCE AT SEPTEMBER 30, 2023

      28,332


      345,462


      1,408


      16,070


      (1,416)


      (376,722)


      13,134
















      Ordinary


      Share




      Capital


      Other

      comprehensive


      Accumulated




      shares


      premium


      Warrants


      reserve


      loss


      deficit


      Total


      in USD thousands

      BALANCE AT JANUARY 1, 2024

      31,355


      355,482


      1,408


      17,000


      (1,416)


      (390,606)


      13,223

      CHANGES FOR NINE MONTHS ENDED
           SEPTEMBER 30, 2024:














      Issuance of share capital and warrants, net

      3,056


      (3,056)


      -


      -


      -


      -


      -

      Employee stock options exercised

      19


      56


      -


      (48)


      -


      -


      27

      Employee stock options expired

      -


      523


      -


      (523)


      -


      -


      -

      Employee stock options forfeiture

      -


      -


      -


      (88)


      -


      -


      (88)

      Share-based compensation  

      -


      -


      -


      1,377


      -


      -


      1,377

      Comprehensive loss for the period

      -


      -


      -


      -


      -


      (6,034)


      (6,034)

      BALANCE AT SEPTEMBER 30, 2024

      34,430


      353,005


      1,408


      17,718


      (1,416)


      (396,640)


      8,505

      BioLineRx Ltd.

      CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

      (UNAUDITED)




      Nine months ended September 30,


      2023


      2024


      in USD thousands





      CASH FLOWS - OPERATING ACTIVITIES




      Net loss for the period

      (46,730)


      (6,034)

      Adjustments required to reflect net cash used in operating activities
      (see appendix below)

      19,131


      (29,229)

      Net cash used in operating activities

      (27,599)


      (35,263)





      CASH FLOWS – INVESTING ACTIVITIES




      Investments in short-term deposits

      (13,882)


      (26,350)

      Maturities of short-term deposits

      36,000


      44,626

      Purchase of property and equipment

      (100)


      (59)

      Purchase of intangible assets

      (179)


      -

      Net cash provided by investing activities

      21,839


      18,217





      CASH FLOWS – FINANCING ACTIVITIES




      Issuance of share capital and warrants, net of issuance costs

      1,896


      5,358

      Exercise of warrants

      2,530


      -

      Employee stock options exercised

      15


      27

      Net proceeds from loan

      -


      19,223

      Repayments of loan

      (802)


      (2,461)

      Repayments of lease liabilities

      (323)


      (380)

      Net cash provided by financing activities

      3,316


      21,767





      INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

      (2,444)


      4,721

      CASH AND CASH EQUIVALENTS - BEGINNING

         OF PERIOD

      10,587


      4,255

      EXCHANGE DIFFERENCES ON CASH AND CASH
         EQUIVALENTS

      (416)


      (140)

      CASH AND CASH EQUIVALENTS - END OF PERIOD

      7,727


      8,836





      BioLineRx Ltd.

      APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

      (UNAUDITED)




      Nine months ended September 30,


      2023


      2024


      in USD thousands









      Adjustments required to reflect net cash used in operating activities:




      Income and expenses not involving cash flows:




      Depreciation and amortization

      678


      2,213

      Exchange differences on cash and cash equivalents

      416


      140

      Fair value adjustments of warrants

      13,968


      (13,567)

      Share-based compensation

      1,392


      1,289

      Interest on short-term deposits

      136


      126

      Interest on loan

      2,170


      1,269

      Exchange differences on lease liability 

      (122)


      67

      Issuance cost of warrants

      -


      642


      18,638


      (7,821)





      Changes in operating asset and liability items:




         Increase in trade receivables

      -


      (3,253)

         Decrease (increase) in prepaid expenses and other receivables

      (566)


      357

         Increase in inventory

      (1,352)


      (1,591)

      Increase (decrease) in accounts payable and accruals

      2,411


      (6,219)

      Decrease in contract liabilities

      -


      (10,702)


      493


      (21,408)


      19,131


      (29,229)









      Supplemental information on interest received in cash

      1,268


      1,644





      Supplemental information on interest paid in cash

      833


      1,586





      Supplemental information on non-cash transactions:




            Changes in right-of-use asset and lease liabilities

      66


      305





      SOURCE BioLineRx Ltd.

      Modal title

      Also from this source

      BioLineRx to Report Third Quarter 2026 Results on November 23, 2026

      BioLineRx to Report Third Quarter 2026 Results on November 23, 2026

      BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

      BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital

      BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital

      BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Health Care & Hospitals

      Health Care & Hospitals

      Pharmaceuticals

      Pharmaceuticals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.